

CORRECTION

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer


Manish A. Shah, Zev A. Wainberg, Daniel V. T. Catenacci, Howard S. Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C. Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P. Bottaro

Notice of republication

This article was republished on October 20, 2020, to remove a Supporting Information file. Please download this article again to view the correct version.

Reference

1. Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, et al. (2013) Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE 8(3): e54014. <https://doi.org/10.1371/journal.pone.0054014> PMID: 23516391



OPEN ACCESS

Citation: Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, et al. (2021) Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS ONE 16(12): e0261994. <https://doi.org/10.1371/journal.pone.0261994>

Published: December 23, 2021

Copyright: © 2021 Shah et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.